MarketCapExport financials
X4 Pharmaceuticals (XFOR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
X4 Pharmaceuticals Financial Ratios 2025-2011 | XFOR
Brief overview of X4 Pharmaceuticals's market valuation
The review covers five available annual periods spanning 2021 to 2025.
The valuation comparison uses P/S 27.52x (median 19.48x), P/B 0.96x (median 0.82x). Valuation is 28.9% above five-year reference levels. The premium requires support from earnings and returns.
Current measures of operating quality are ROE -42.5%, ROA -27.3%, ROCE -46.6%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
Overall picture
X4 Pharmaceuticals's profile looks stretched: price anticipates improvement that current quality ratios do not yet confirm.
Annual Financial Ratios X4 Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-2.3 | -0.8 | -0.1 | -0.6 | -0.6 | -2.5 | -1.9 | -0.9 | -0.8 | - | - | - | - | - | - |
P/S |
27.5 | 10.9 | - | - | - | 52.3 | - | 11.4 | - | - | - | - | - | - | - |
EPS |
-1.9 | -5.6 | -17.1 | -1.5 | -4.0 | -3.1 | -4.6 | -79.2 | -54.6 | -44.8 | - | - | - | - | - |
EV (Enterprise Value) |
66 M | 96.9 M | 4.71 M | 15.1 M | 24 M | 128 M | 4.45 M | 46.3 M | 22.9 M | 60.7 M | 43.8 M | - | - | - | - |
EBITDA per Share |
-2.02 | -5.31 | -18.1 | -1.37 | -3.29 | -2.96 | -4.14 | -17.8 | -92.7 | - | - | - | - | - | - |
EV/EBITDA |
-0.8 | -2.7 | -0.0 | -0.2 | -0.3 | -1.9 | 0.1 | -0.4 | 1.3 | - | - | - | - | - | - |
PEG |
-0.01 | -0.0 | -0.0 | 0.01 | - | -0.08 | -0.03 | -0.01 | 0.01 | - | - | - | - | - | - |
P/B |
1.0 | 1.3 | 0.2 | 0.7 | 0.8 | 2.2 | 0.8 | 1.9 | 0.5 | - | - | - | - | - | - |
P/CF |
-2.1 | -0.2 | -0.1 | -0.7 | -0.7 | -2.7 | -2.1 | -1.0 | -1.0 | - | - | - | - | - | - |
ROE % |
-42.51 | -169.08 | -197.98 | -126.76 | -137.70 | -85.35 | -40.87 | -199.17 | -57.71 | - | - | - | - | - | - |
ROA % |
-27.27 | -25.57 | -68.70 | -60.33 | -75.69 | -50.57 | -32.86 | -119.49 | -41.69 | - | - | - | - | - | - |
ROCE % |
-46.64 | -164.35 | -210.42 | -118.25 | -132.13 | -82.25 | -31.61 | -139.53 | -45.72 | - | - | - | - | - | - |
Current Ratio |
2.8 | 1.2 | 1.5 | 1.9 | 2.2 | 2.5 | 13.7 | 6.5 | 7.4 | - | - | - | - | - | - |
DSO |
46.1 | 75.1 | - | - | - | - | - | 298.2 | - | - | - | - | - | - | - |
DIO |
89.3 | 645.0 | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
453.9 | 4022.8 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
135.4 | 720.1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
-318.4 | -3302.6 | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios X4 Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.13 | -0.16 | -0.69 | -3.47 | 0.04 | - | -5.48 | 13.59 | -7.77 | - | -0.01 | -0.33 | -0.16 | - | -0.26 | -0.6 | -0.72 | - | -0.76 | -0.74 | -1.3 | - | -0.87 | -0.76 | -0.56 | - | -1.22 | -1.02 | -6.67 | -0.65 | -20.39 | -14.83 | -17.7 | -1.68 | -22.6 | -11.13 | -10.49 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.12 | -0.16 | - | - | -1.31 | - | -5.12 | 10.7 | -5.58 | - | - | - | -0.2 | - | -0.24 | -0.58 | -0.63 | - | -0.7 | -0.72 | -0.86 | - | -0.83 | -0.73 | -0.53 | - | -1.16 | -1.01 | -6.06 | - | -18.4 | -13.8 | -13.3 | - | -25.1 | -10.8 | -11.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-719.02 | -707.40 | -756.93 | -612.37 | -4960.87 | -4962.10 | -4965.51 | -4986.45 | -5129.10 | -132.39 | -167.29 | -234.41 | -196.10 | -149.62 | -178.99 | -166.58 | -113.82 | -69.64 | -93.61 | -85.03 | -77.85 | -60.07 | -73.78 | -60.17 | -47.78 | -32.48 | -20.34 | 4.53 | 22.71 | 40.68 | 53.66 | 22.74 | 5.19 | -13.54 | -19.76 | -9.72 | -9.17 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-56.58 | -49.98 | -63.09 | -1.73 | -23.40 | -23.61 | -24.94 | -36.48 | -98.91 | -52.77 | -71.80 | -92.52 | -77.13 | -57.82 | -71.69 | -52.65 | -64.25 | -42.20 | -56.40 | -51.99 | -47.19 | -35.59 | -46.61 | -40.74 | -35.18 | -26.12 | -120.22 | -195.71 | -248.06 | -315.38 | -235.04 | -162.81 | -109.15 | -41.69 | -14.28 | -7.02 | -6.63 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-727.83 | -758.44 | -804.26 | -684.33 | -3623.07 | -3581.91 | -3622.17 | -3602.51 | -3734.50 | -135.18 | -167.76 | -195.90 | -200.47 | -143.77 | -171.60 | -160.77 | -109.44 | -66.66 | -89.99 | -82.28 | -75.07 | -57.99 | -71.13 | -58.19 | -46.13 | -31.60 | -20.51 | 0.90 | 19.20 | 27.28 | 5.04 | -15.66 | -33.85 | -41.78 | -22.24 | -9.61 | -9.93 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.6 | 2.6 | 1.6 | 1.0 | 1.2 | 1.2 | 1.5 | 1.8 | 1.0 | 1.5 | 1.6 | 1.6 | 1.7 | 1.9 | 2.2 | - | 2.0 | 2.2 | 2.3 | 2.7 | 3.0 | 2.5 | 2.5 | 2.5 | 2.5 | 5.1 | 5.1 | 5.1 | 5.1 | 0.5 | 0.5 | 0.5 | 0.5 | 3.6 | 3.6 | 3.6 | 3.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
60.1 | 36.6 | 59.3 | 43.3 | 80.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
254.1 | 772.6 | 1658.9 | 2634.5 | 190.9 | - | 3329.0 | 2880.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 59.3 | 43.3 | 80.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | -1599.6 | -2591.2 | -110.9 | - | -3329.0 | -2880.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company X4 Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
- | - | - |  Russia |
 |
ОЗОН Фармацевтика
OZPH
|
- | - | - | Russia |
 |
Промомед
PRMD
|
- | - | - | Russia |
 |
Ionis Pharmaceuticals
IONS
|
$ 43.5 | 0.62 % | $ 6.96 B |  USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 31.25 | 0.88 % | $ 1.81 B | USA |
 |
Foghorn Therapeutics
FHTX
|
$ 2.0 | 0.74 % | $ 126 M | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 2.0 | 0.5 % | $ 197 M | USA |
 |
Kamada Ltd.
KMDA
|
$ 8.0 | 1.34 % | $ 461 M |  Israel |
 |
Intellia Therapeutics
NTLA
|
$ 12.75 | 4.0 % | $ 1.38 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 14.5 | 3.19 % | $ 1.43 B | USA |
 |
Viridian Therapeutics
VRDN
|
$ 19.0 | 2.16 % | $ 1.93 B | USA |
 |
AbbVie
ABBV
|
$ 265.76 | 1.12 % | $ 470 B | USA |
 |
AbCellera Biologics
ABCL
|
$ 13.78 | 0.29 % | $ 4.12 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
$ 5.11 | 1.59 % | $ 271 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.67 | 4.94 % | $ 895 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 20.11 | 0.8 % | $ 3.39 B | USA |
 |
Achieve Life Sciences
ACHV
|
$ 7.01 | 0.13 % | $ 306 M | USA |
 |
AC Immune SA
ACIU
|
$ 2.71 | 0.55 % | $ 273 M |  Schweiz |
 |
Aclaris Therapeutics
ACRS
|
$ 4.27 | 0.79 % | $ 523 M | USA |
 |
Adagene
ADAG
|
$ 2.8 | 0.28 % | $ 165 M |  China |
 |
ADC Therapeutics SA
ADCT
|
$ 1.23 | 8.85 % | $ 156 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
$ 4.35 | 5.58 % | $ 2.91 M | USA |
 |
ADMA Biologics
ADMA
|
$ 10.11 | 4.01 % | $ 2.41 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 29.84 | 5.26 % | $ 4.53 B | USA |
 |
Agenus
AGEN
|
$ 8.73 | 4.43 % | $ 260 M | USA |
 |
AIM ImmunoTech
AIM
|
$ 0.19 | 5.56 % | $ 308 K | USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.91 | 5.26 % | $ 234 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
$ 8.76 | 0.46 % | $ 590 B |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.92 | 4.88 % | $ 55.3 M | USA |
 |
Alector
ALEC
|
$ 1.99 | 9.94 % | $ 205 M | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.4 | 0.36 % | $ 53.4 M | USA |
 |
Alkermes plc
ALKS
|
$ 42.76 | 2.42 % | $ 7.04 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
$ 1.5 | 0.33 % | $ 331 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 219.89 | 0.08 % | $ 28.8 B | USA |
 |
Altimmune
ALT
|
$ 2.67 | 0.36 % | $ 235 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.21 | 1.23 % | $ 64.9 M | USA |
 |
Amgen
AMGN
|
$ 402.98 | 0.08 % | $ 217 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.37 | 0.39 % | $ 1.19 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 12.09 | 0.31 % | $ 5.02 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
$ 20.35 | 0.25 % | $ 6.38 B | USA |
 |
AnaptysBio
ANAB
|
$ 49.2 | 1.38 % | $ 1.43 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 19.73 | 3.3 % | $ 283 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 72.58 | 0.55 % | $ 1.46 B | USA |
 |
Annexon
ANNX
|
$ 4.2 | 0.24 % | $ 651 M | USA |
 |
Annovis Bio
ANVS
|
$ 1.2 | 1.69 % | $ 24.7 M | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.68 | 0.16 % | $ 4.45 M | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.8 | 2.27 % | $ 568 K | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.57 | 0.44 % | $ 489 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 14.66 | 12.51 % | $ 401 M | Israel |
 |
Ardelyx
ARDX
|
$ 3.39 | 1.5 % | $ 817 M | USA |